IBIO earnings analysis
What we found in IBIO's 10-K: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
iBio transitioned to a clinical-stage biotechnology company, with IBIO-600 in Phase 1 and IBIO-610 targeted for first-in-human testing in the first half of calendar 2027. However, fiscal 2026 remained financially weak: revenue fell to $0.1 million from $0.4 million, net loss widened to $33.044 million from $18.377 million, and operating cash use increased to $23.218 million from $15.304 million. The approximately $88 million liquidity position extends the stated runway into the fourth quarter of fiscal 2028, but the concentrated early-stage pipeline, foreign-trial/regulatory uncertainty and significant potential dilution outweigh the near-term clinical progress.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- IBIO-600 Reached Phase 1
- IBIO-600 entered human testing: the company dosed its first participant in June 2026, enrolled 31 participants in the first four Phase 1 cohorts in Australia, and expects study completion in the second half of 2027.
- IBIO-610 Advances Toward 2027 Trial
- IBIO-610 advanced toward the clinic after preclinical data showed 98% and 97% reductions in active Activin E at weeks 4 and 8, respectively, in obese NHPs. The company anticipates commencing first-in-human trials in the first half of calendar 2027.
- Integrated AI Platform Supports Speed
- The AI Drug Discovery Platform combines epitope steering, StableHu and mammalian-display screening; management says it can progress from concept to development-ready antibody in as little as seven months and from concept to in-vivo proof-of-concept within weeks.
- Liquidity Extended Into Fiscal 2028
- Liquidity improved materially following approximately $46.4 million of net proceeds from the August 2025 offering, $24.3 million from the January 2026 private placement and $32.8 million of net warrant-exercise proceeds. Cash, cash equivalents and investments in debt securities totaled approximately $88 million at June 30, 2026.
- Debt Repayment Strengthened Balance Sheet
- The company reduced debt exposure during fiscal 2026: it paid approximately $652,000 to retire the 2024 Term Note and ended the year with a zero balance on the equipment financing and term promissory note.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Pipeline Concentrated After Strategic Pivot
- Following the fiscal 2026 pivot away from immune-oncology, IBIO-600 is the only product candidate in human clinical trials and the other candidates remain preclinical. The company states that its pipeline is now concentrated primarily in obesity, cardiometabolic and cardiopulmonary diseases, increasing exposure to setbacks in one therapeutic area; it also fully impaired IBIO-101 by recording a $5.003 million charge.
- Clinical and Foreign-Regulatory Execution Risk
- The lead program depends on an early-stage Australian trial: 31 of 32 planned participants had been enrolled in the SAD portion, but each participant is expected to be monitored for approximately nine months. The trial is being conducted under Australia’s CTN scheme rather than an FDA-approved IND, and the filing states that the FDA may not accept the foreign-study data without additional studies or analyses.
- Substantial Dilution and Funding Dependence
- Shareholder dilution remains material as development spending continues. Shares issued and outstanding increased from 19,349,201 at June 30, 2025 to 55,698,561 at June 30, 2026, while up to 95,832,863 pre-funded-warrant shares remained issuable at year-end; the company also has a $100 million ATM facility and states that it has no committed sources of future funding.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.32
- Segment
- Single reportable segment: biotechnology company leveraging AI and ML to develop hard-to-drug precision antibodies
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management stated that approximately $88 million of cash, cash equivalents and debt-security investments is expected to support operations into the fourth quarter of fiscal 2028.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 12, 2026
- iBio, Inc. reported no revenue for Q3 FY 2026, with an eps of -$0.06, slightly worse than the previous year's -$0.49. The company continues its preclinical development, notably progressing towards clinical trials for…
- 10-Q · February 10, 2026
- iBio reported zero revenue for the quarter (vs $200,000 in the prior-year quarter) and a three-month net loss of $8.993 million (loss per share $0.09), compared with a net loss of $4.364 million (loss per share $0.48)…
- 10-Q · November 12, 2025
- iBio reported revenue of $100 (reported in the filing in thousands) for the three months ended September 30, 2025 and a net loss of $5,720 (in thousands), or loss per share of $0.11. The company materially strengthened…
- 10-K · September 5, 2025
- iBio, Inc. reports a strategic focus on advancing innovative antibody therapies for obesity and cardiometabolic diseases, leveraging AI in their drug discovery processes. The Company’s 2025 financial results showed a…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing IBIO makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever